vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and Gaming & Leisure Properties, Inc. (GLPI). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $420.0M, roughly 1.4× Gaming & Leisure Properties, Inc.). Gaming & Leisure Properties, Inc. runs the higher net margin — 57.0% vs 40.8%, a 16.2% gap on every dollar of revenue. On growth, Gaming & Leisure Properties, Inc. posted the faster year-over-year revenue change (6.3% vs 5.6%). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 5.0%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Gaming and Leisure Properties, Inc. is a real estate investment trust (REIT) specializing in casino properties, based in Wyomissing, Pennsylvania. It was formed in November 2013 as a corporate spin-off from Penn National Gaming. The company owns 62 casino properties, all of which are leased to other companies.
EXEL vs GLPI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $420.0M |
| Net Profit | $244.5M | $239.4M |
| Gross Margin | 95.6% | — |
| Operating Margin | 39.3% | 79.4% |
| Net Margin | 40.8% | 57.0% |
| Revenue YoY | 5.6% | 6.3% |
| Net Profit YoY | 74.8% | 40.5% |
| EPS (diluted) | $0.89 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | $420.0M | ||
| Q4 25 | $597.8M | $407.0M | ||
| Q3 25 | $568.3M | $397.6M | ||
| Q2 25 | $555.4M | $394.9M | ||
| Q1 25 | $566.8M | $395.2M | ||
| Q4 24 | — | $389.6M | ||
| Q3 24 | $539.5M | $385.3M | ||
| Q2 24 | $637.2M | $380.6M |
| Q1 26 | $244.5M | $239.4M | ||
| Q4 25 | $193.6M | $275.4M | ||
| Q3 25 | $184.8M | $241.2M | ||
| Q2 25 | $159.6M | $151.4M | ||
| Q1 25 | $139.9M | $165.2M | ||
| Q4 24 | — | $223.6M | ||
| Q3 24 | $118.0M | $184.7M | ||
| Q2 24 | $226.1M | $208.3M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | — | ||
| Q3 25 | 96.6% | — | ||
| Q2 25 | 96.5% | — | ||
| Q1 25 | 96.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 96.8% | — | ||
| Q2 24 | 97.2% | — |
| Q1 26 | 39.3% | 79.4% | ||
| Q4 25 | 39.6% | 89.3% | ||
| Q3 25 | 37.6% | 84.8% | ||
| Q2 25 | 33.6% | 61.3% | ||
| Q1 25 | 28.8% | 65.5% | ||
| Q4 24 | — | 79.1% | ||
| Q3 24 | 25.2% | 70.4% | ||
| Q2 24 | 43.3% | 77.1% |
| Q1 26 | 40.8% | 57.0% | ||
| Q4 25 | 32.4% | 67.6% | ||
| Q3 25 | 32.5% | 60.7% | ||
| Q2 25 | 28.7% | 38.4% | ||
| Q1 25 | 24.7% | 41.8% | ||
| Q4 24 | — | 57.4% | ||
| Q3 24 | 21.9% | 47.9% | ||
| Q2 24 | 35.5% | 54.7% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $0.96 | ||
| Q3 25 | $0.65 | $0.85 | ||
| Q2 25 | $0.55 | $0.54 | ||
| Q1 25 | $0.47 | $0.60 | ||
| Q4 24 | — | $0.79 | ||
| Q3 24 | $0.40 | $0.67 | ||
| Q2 24 | $0.77 | $0.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $274.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.2B | $5.0B |
| Total Assets | $2.8B | $13.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | $274.5M | ||
| Q4 25 | $988.5M | — | ||
| Q3 25 | $791.1M | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | — | $560.8M | ||
| Q3 24 | $1.2B | $560.8M | ||
| Q2 24 | $1.0B | $560.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $7.2B | ||
| Q3 25 | — | $7.2B | ||
| Q2 25 | — | $6.9B | ||
| Q1 25 | — | $6.9B | ||
| Q4 24 | — | $7.7B | ||
| Q3 24 | — | $7.4B | ||
| Q2 24 | — | $6.6B |
| Q1 26 | $2.2B | $5.0B | ||
| Q4 25 | $2.2B | $4.6B | ||
| Q3 25 | $2.0B | $4.6B | ||
| Q2 25 | $2.1B | $4.6B | ||
| Q1 25 | $2.2B | $4.2B | ||
| Q4 24 | — | $4.3B | ||
| Q3 24 | $2.3B | $4.3B | ||
| Q2 24 | $2.1B | $4.1B |
| Q1 26 | $2.8B | $13.8B | ||
| Q4 25 | $2.8B | $12.9B | ||
| Q3 25 | $2.7B | $12.8B | ||
| Q2 25 | $2.8B | $12.5B | ||
| Q1 25 | $2.9B | $12.1B | ||
| Q4 24 | — | $13.1B | ||
| Q3 24 | $3.0B | $12.7B | ||
| Q2 24 | $2.8B | $11.8B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.56× | ||
| Q3 25 | — | 1.57× | ||
| Q2 25 | — | 1.51× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.81× | ||
| Q3 24 | — | 1.74× | ||
| Q2 24 | — | 1.60× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | — |
| Free Cash FlowOCF − Capex | $332.4M | — |
| FCF MarginFCF / Revenue | 55.5% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | 1.36× | — |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $1.1B | ||
| Q3 25 | $49.0M | $240.3M | ||
| Q2 25 | $211.4M | $293.4M | ||
| Q1 25 | $240.3M | $252.5M | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $271.3M | $270.4M | ||
| Q2 24 | $119.5M | $252.1M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | — | ||
| Q3 25 | $46.2M | $183.0M | ||
| Q2 25 | $208.5M | $272.3M | ||
| Q1 25 | $236.3M | $239.6M | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $263.1M | $261.5M | ||
| Q2 24 | $113.0M | $245.0M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | — | ||
| Q3 25 | 8.1% | 46.0% | ||
| Q2 25 | 37.5% | 69.0% | ||
| Q1 25 | 41.7% | 60.6% | ||
| Q4 24 | — | 275.3% | ||
| Q3 24 | 48.8% | 67.9% | ||
| Q2 24 | 17.7% | 64.4% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.5% | 14.4% | ||
| Q2 25 | 0.5% | 5.3% | ||
| Q1 25 | 0.7% | 3.3% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 1.5% | 2.3% | ||
| Q2 24 | 1.0% | 1.9% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | 4.10× | ||
| Q3 25 | 0.27× | 1.00× | ||
| Q2 25 | 1.32× | 1.94× | ||
| Q1 25 | 1.72× | 1.53× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | 2.30× | 1.46× | ||
| Q2 24 | 0.53× | 1.21× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
GLPI
Segment breakdown not available.
